<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985866</url>
  </required_header>
  <id_info>
    <org_study_id>iDCL</org_study_id>
    <secondary_id>UC4DK108483</secondary_id>
    <nct_id>NCT02985866</nct_id>
  </id_info>
  <brief_title>The International Diabetes Closed Loop (iDCL) Trial: Protocol 1</brief_title>
  <acronym>iDCL</acronym>
  <official_title>Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stacey Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TypeZero Technologies, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostic Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the efficacy and safety of home use of a
      Control-to-Range (CTR) closed-loop (CL) system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol is a 3-month parallel group multi-center randomized trial designed to compare
      Control-to-Range (CTR) closed-loop (CL) with sensor augmented pump therapy (SAP).
      Approximately 126 subjects will be entered into the randomized trial at approximately seven
      clinical sites in the United States, such that at least 110 subjects complete the randomized
      trial. A maximum of 200 subjects may be enrolled in the study in order to achieve the goal of
      randomizing 126 subjects.

      In order to have a broad range of glycemic control among the subjects, a study goal will be
      to have a minimum of 50 subjects with HbA1c ≥ 7.5% and 50 with HbA1c &lt; 7.5%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing differences between baseline and 3 months post randomization periods, the first co-primary is superiority in CGM-measured time below 70 mg/dL and the second co-primary is non-inferiority in CGM-measured time above 180 mg/dL.</measure>
    <time_frame>3 months for both measurements</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor Augmented Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Pancreas</intervention_name>
    <description>Use of CTR at home for 3 months</description>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <other_name>Control-to-Range (CTR) closed-loop (CL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensor Augmented Therapy</intervention_name>
    <description>Use of personal pump with study CGM &amp; glucometer at home for 3 months</description>
    <arm_group_label>Sensor Augmented Therapy</arm_group_label>
    <other_name>SAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 1 year

          2. Use of an insulin pump for at least 6 months

          3. Age ≥14 years old

          4. HbA1c level &lt;10.5% at screening

          5. For females, not currently known to be pregnant

          6. Willingness not to add glucose-lowering agents (such as Pramlintide, Metformin, GLP-1
             analogs, SGLT2 inhibitors) during the study

          7. Willingness, if not assigned to the closed-loop group, to avoid use of any closed-loop
             control system for the duration of the clinical trial

          8. Willingness to suspend use of any personal CGM for the duration of the clinical trial
             once the unblinded study CGM is in use

          9. Willingness to establish network connectivity on at least a weekly basis either via
             local Wifi network or via a study-provided cellular service

         10. Currently using no insulins other than one of the following rapid-acting insulins at
             the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin
             glulisine (Apidra)

         11. Investigator has confidence that the subject can successfully operate all study
             devices and is capable of adhering to the protocol

         12. For subjects less than 18 years old, living with one or more parent/legal guardian
             (referred to subsequently as diabetes care partner) committed to participating in
             study training for emergency procedures for severe hypoglycemia and able to contact
             the subject in case of an emergency

        Exclusion Criteria:

          1. Medical need for chronic acetaminophen

          2. Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs,
             SGLT2 inhibitors) in the 3 months prior to enrollment

          3. Hemophilia or any other bleeding disorder

          4. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk including any contraindication to the use of any of the
             study devices per FDA labeling

          5. Participation in another pharmaceutical or device trial at the time of enrollment or
             during the study

          6. Use of a closed-loop system within the last month prior to enrollment

          7. Employed by, or having immediate family members employed by TypeZero Technologies, LLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris P. Kovatchev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey M. Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey M. Anderson, MD</last_name>
    <phone>434-982-0945</phone>
    <email>sg4c@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Emory, RN</last_name>
    <phone>434-243-3992</phone>
    <email>ee9m@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Sansum Diabetes Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Pinsker, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Camille Andre</last_name>
      <phone>805-682-7640</phone>
      <phone_ext>217</phone_ext>
      <email>candre@sansum.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Pinsker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mei Mei Church, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Buckingham, MD</last_name>
      <phone>650-723-5791</phone>
      <email>bbendo@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Liana Hsu</last_name>
      <phone>650-725-3939</phone>
      <email>ljhsu@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Buckingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Paul Wadwa, MD</last_name>
      <phone>303-724-2323</phone>
      <email>paul.wadwa@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Jost, MPH RD CDE</last_name>
      <phone>(303) 724-7313</phone>
      <email>emily.jost@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>R. Paul Wadwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University (Joslin Diabetes Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <phone>617-732-2603</phone>
      <email>lori.laffel@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Louise Ambler-Osborn, CPNP</last_name>
      <phone>617-732-2603</phone>
      <email>louise.ambler-osborn@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Doyle, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly McCrady-Spitzer</last_name>
      <phone>507-255-5916</phone>
      <email>McCradySpitzer.Shelly@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yogish C. Kudva, MBBS, MD</last_name>
      <email>kudva.yogish@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yogish Kudva, MBBS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Levy, MD, CDE</last_name>
      <phone>212-241-9089</phone>
      <email>selassie.ogyaadu@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Levister, ANP-C, MS</last_name>
      <phone>212-241-5177</phone>
      <email>Camilla.Levister@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Levy, MD, CDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey M. Anderson, MD</last_name>
      <phone>434-982-0945</phone>
      <email>sg4c@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Emory, RN</last_name>
      <phone>434-243-3992</phone>
      <email>ee9m@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sue A. Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Gonder-Fredrick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>October 28, 2017</last_update_submitted>
  <last_update_submitted_qc>October 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Stacey Anderson</investigator_full_name>
    <investigator_title>CDT Medical Director</investigator_title>
  </responsible_party>
  <keyword>Artificial Pancreas</keyword>
  <keyword>Closed Loop Control</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>inControl Diabetes Management Platform</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH's Data Sharing Policy on sharing research resources for research purposes to the scientific community will be followed. Data will be stored in a Data Archive Database includes CGM-insulin delivery time series, meal content, boluses, &amp; exercise will be deidentified &amp; retrievable only by subject ID number. Individual patterns of demographic &amp; insulin treatment parameters leave open a remote possibility of deductive disclosure of subjects with unusual characteristics. Thus, data will be made available only under a Data-Sharing Agreement that includes: (1) a commitment to using the data only for research purposes &amp; not to identify participants; (2) a commitment to securing the data using appropriate computer technology; &amp; (3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

